期刊文献+

沉默MACC1的表达对卵巢癌细胞系SKOV-3顺铂化疗敏感性的影响 被引量:7

Effect of silencing MACC1 gene on cisplatin chemosensibility of ovarian cancer cell line SKOV-3
下载PDF
导出
摘要 目的:探讨沉默结肠癌转移相关基因1(MACC1)对卵巢癌上皮性癌细胞SKOV-3顺铂化疗敏感性的影响。方法:SKOV-3细胞分为shRNA转染组(重组质粒psuper-EGFP-s3转染)、空质粒转染组(psuper-EGFP-neo转染)和对照组(未作转染),采用RT-PCR法和Western blot法检测各组细胞MACC1 mRNA和蛋白的表达,MTT法检测细胞对顺铂的耐药性。结果:3组SKOV-3细胞MACC1 mRNA和蛋白表达比较,差异有统计学意义(P<0.05),shRNA转染组较未转染组和空质粒组下降。shRNA转染组对顺铂的IC50较对照组和空质粒转染组下降(P<0.05)。结论:沉默MACC1的表达能增加卵巢癌SKOV-3细胞对顺铂的敏感性。 Aim: To investigate the relationship of RNA interfering MACC1 and cisplatin sensibility of ovarian cancer cell line SKOV-3. Methods: SKOV-3 cells were divided into 3 groups: shRNA group( recombinant plasmid psuper-EGFPs3 transfected SKOV-3 cells),empty plasmid transfection group( psuper-EGFP-neo transfected SKOV-3 cells) and control group( non transfected SKOV-3 cells). RT-PCR and Western blot were used to detect the expressions of MACC1 mRNA and protein. IC50 of cisplatin in different groups was determined by MTT assay. Results: The expressions of MACC1 mRNA and protein in the 3 groups were significantly different( P〈0. 05),and those of the shRNA transfection group were lower than those in the control group and empty plasmid group. The shRNA transfection group had lower IC50 than the control group and empty plasmid group( P〈0. 05). Conclusion: The sensitivity of SKOV-3 cells to cisplatin could be enhanced by RNA interfering MACC1 gene.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2016年第1期92-95,共4页 Journal of Zhengzhou University(Medical Sciences)
基金 河南省重点科技攻关计划项目122102310545
关键词 结肠癌转移相关因子1 RNA干扰 顺铂敏感性 卵巢癌 SKOV-3细胞 metastasis-associated in colon cancer 1 RNA interference cisplatin sensibility ovarian cancer SKOV-3 cell
  • 相关文献

参考文献3

二级参考文献28

  • 1George F. VANDE WOUDE.HGF/SF-Met signaling in tumor progression[J].Cell Research,2005,15(1):49-51. 被引量:25
  • 2李海刚,张惠忠,吕志强,沈溪明,王李莉,巴基.非小细胞肺癌HGF和ECE的表达及其与淋巴结转移和预后的关系[J].肿瘤,2007,27(7):553-556. 被引量:2
  • 3Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics[J]. 2002, CA Cancer J Clin, 2005, 55(2): 74-108.
  • 4Zhou HY, Pon YL, Wong AS. HGF/MET signaling in ovarian cancer[J]. Curr Mol Med, 2008, 8(6): 469-80.
  • 5Stein U, Walther W, Arlt F, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis [J]. Nat Med, 2009, 15(1): 59-67.
  • 6Zillhardt M, Christensen JG, Lengyel E. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis[J]. Neoplasia, 2010, 12(1): 1-10.
  • 7Kokoszyfiska K, Krynski J, Rychlewski L, et al. Unexpected domain composition of MACC 1 links MET signaling and apoptosis [J]. Acta Biochim Pol, 2009, 56(2): 317-23.
  • 8Boardman LA. Overexpression of MACC1 leads to downstream activation of HGF/MET and potentiates metastasis and recurrence of colorectal cancer[J]. Genome Med, 2009, 1(4): 36.
  • 9Shirahata A, Shinmura K, Kitamura Y, et al. MACC1 as a marker for advanced colorectal carcinoma[J]. Anticancer Res, 2010, 30(7): 2689-92.
  • 10Shirahata A, Sakata M, Kitamura Y, et al. MACC 1 as a marker for peritoneal-disseminated gastric carcinoma [J]. Anticancer Res, 2010, 30(9): 3441-4.

共引文献42

同被引文献59

  • 1沈铿,李孟达,丰有吉,马丁,李子庭,谢辛,孔北华,崔恒,宋垒,彭芝兰,李力,吴鸣,陈亦乐,刘继红,吴令英,郎景和,中国妇科肿瘤学组.泰素周疗和三周疗法作为卵巢癌一线化疗的多中心对照研究[J].中华医学杂志,2005,85(30):2099-2103. 被引量:16
  • 2王震,刘乾,陈琦,朱荣,朱虹光.NDRG1基因与乳腺癌转移的关系及其转染对乳腺癌细胞株增殖及侵袭力的影响[J].中华病理学杂志,2006,35(6):333-338. 被引量:31
  • 3Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
  • 4Bray F, Ren JS, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008[J]. IntJ Cancer, 2013, 132(5): 1133-1145.
  • 5Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008[J]. CA Cancer J Clin, 2008, $8(2): 71-96.
  • 6Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 vl.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. [2016-03-28]. http://globocan. iarc.fr.
  • 7Thigpen T, Dubois A, McAlpine J, et aI. First-line therapy in ovarian cancer trials[J]. IntJ Gynecol Cancer, 2011, 21(4): 756- 762.
  • 8. Baird RD, Tan DS, Kaye SB. Weekly paclitaxel in the treatment of recurrent ovarian cancer[J]. Nat Rev Clin Oncol, 2010, 7(10): 575-582.
  • 9Katsumata N, Yasuda M, Isonishi S,et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial[J]. Lancet Oncol, 2013, 14(10): 1020-1026.
  • 10Higgins Jp, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011 ]. The Cochrane Collaboration, 2011. http://www.cochrane- handbook.org.

引证文献7

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部